We are using in vitro and in vivo reprogramming system to investigate how cellular plasticity is regulated during physiological and pathological processes. Our aim is to understand how aberrant cellular plasticity is induced during tumorigenesis and how to modulate cellular plasticity for regeneration especially in ageing related diseases.
With more than 19.3 million new cases in 2020 worldwide, including nearly 400,000 in France, cancer is a common disease that affects or will affect us all one day, directly or indirectly. It is […]
Ageing & Longevity
According to the WHO, the global percentage of people aged of more than 60 years will double from 11 to 22% between 2000 and 2050. Nowadays most of the elderly die of non-transmissible diseases […]
What’s best to study humans and their infectious deseases than Human emulation system ? It’s now possible at Pasteur to develop real Organs-on-chips with cells from different sources, patient derived or cell line. At […]
Cellular plasticity and Ageing
Ageing is associated with losing normal cellular plasticity (regeneration capacity) while acquiring abnormal cellular dys-plasticity (cancer). Cellular reprogramming is associated with a gain in the potential for differentiation and self-renewal. Could common pathways be […]
Cellular plasticity and Cancer
Aberrant cellular plasticity (“dys-plasticity”) could occur in vivo, which contributes significantly to disease development, especially in cancer. Recently, we showed p27-/- cells are dysplastic due to the derepression of Sox2, an essential pluripotency gene. […]
2014 – present G5 Group Leader, Institut Pasteur
2012 – 2014 Staff scientist, Tumor Suppression Group, Spanish National Research Centre
2007 – 2012 Postdoctral Fellow, Tumor Suppression Group, Spanish National Research Centre
2001 – 2007 Ph.D. in Molecular Medicine, University of Texas Health Science Center at San Antonio
San Antonio, Texas, USA
1995 – 1999 Bachelor in Ecology, FuDan University,
2022Amphiregulin mediates non-cell-autonomous effect of senescence on reprogramming., Cell Rep 2022 Jul; 40(2): 111074.
2019Detecting Cellular Senescence in Reprogramming, Methods Mol. Biol. 2019;1896:1-10.
2017Evaluation of Injury-induced Senescence and In Vivo Reprogramming in the Skeletal Muscle, J Vis Exp 2017 10;(128).
2017Δ133p53 represses p53-inducible senescence genes and enhances the generation of human induced pluripotent stem cells, Cell Death Differ. 2017 Jun;24(6):1017-1028.
2016Injury-Induced Senescence Enables In Vivo Reprogramming in Skeletal Muscle, Cell Stem Cell 2017 03;20(3):407-414.e4.
2016Genomic stability during cellular reprogramming: Mission impossible? Mutat Res. 2016 Jun;788:12-6,, Mutat Res. 2016 Jun;788:12-6.
2015Limiting replication stress during somatic cell reprogramming reduces genomic instability in induced pluripotent stem cells, Nat Commun. 2015 Aug 21;6:8036.
2014Deletion of individual Ku subunits in mice causes an NHEJ-independent phenotype potentially by altering apurinic/apyrimidinic site repair, PLoS ONE 2014;9(1):e86358.
2013Reprogramming activity of NANOGP8, a NANOG family member widely expressed in cancer, Oncogene 2014 May;33(19):2513-9.
2013Ku80-deleted cells are defective at base excision repair, Mutat. Res. 2013 May-Jun;745-746:16-25.
+View full list of publications